Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
European equities traded in the US as American depositary receipts were edging lower late Wednesday morning, declining 0.18% to 1,435.51 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company argenx and telecommunications operator Telefonica , which rose 1.2% and 0.9% respectively. They were followed by biopharmaceutical company Calliditas Therapeutics and financial services company Banco Bilbao Vizcaya Argentaria , which were up 0.7% and 0.4% respectively.
The decliners from continental Europe were led by biotech firm BioNTech and telecommunications operator VEON , which fell 4.4% and 2.9% respectively. They were followed by semiconductor company Sequans Communications and biopharmaceutical company DBV Technologies , which were down 2.3% and 1.6% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Mereo BioPharma Group and biotech firm Autolus Therapeutics , which advanced 8.1% and 2.6% respectively. They were followed by biopharmaceutical company Akari Therapeutics and cruise line operator Carnival , which increased 2.7% and 2.1% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies TC Biopharm and NuCana , which dropped 4.7% and 1.9% respectively. They were followed by software firm Endava and biopharmaceutical company Biodexa Pharmaceuticals , which lost 3.4% and 1.2% respectively.
European equities traded in the US as American depositary receipts were trending modestly lower late Tuesday morning, declining 0.16% to 1,445.76 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Genfit and pharmaceutical company Ascendis Pharma , which rose 6.8% and 5.7% respectively. They were followed by internet advertising firm Criteo and biotech firm BioNTech , which increased 2.3% and 0.5% respectively.
The decliners from continental Europe were led by furniture maker Natuzzi and medical device maker EDAP TMS , which fell 6.7% and 3.3% respectively. They were followed by biotech firm Evaxion Biotech and biopharmaceutical company DBV Technologies , which lost 2.8% and 1.5% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals and Akari Therapeutics , which were up 2% and 3.6% respectively. They were followed by pharmaceutical company Silence Therapeutics and insurance company Prudential , which increased 3.4% and 1.3% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana , which tumbled 31.4%, followed by tobacco company British American Tobacco , which was down 2.7%. Pharmaceutical company GSK and medical device maker Smith & Nephew dropped 1.7% and 1.2% respectively.
MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of BioNTech’s “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Tuesday, October 1st, 2024 in London, United Kingdom. The event will provide an overview of BioNTech’s and InstaDeep’s AI strategy and capabilities, and the application of AI in BioNTech’s pipeline and internal processes.
The live webcast of the event will be available via this link.
A replay of the webcast will be available shortly after the event’s conclusion and archived on BioNTech’s website for one year after.
About BioNTechBiopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
CONTACTS
Media RelationsJasmina Alatovic+49 (0) 6131 9084 1513Media@biontech.de
Investor RelationsVictoria Meissner, M.D.Investors@biontech.de
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.